Windfeld-Mathiasen Josefine, Tulstrup Morten, Heerfordt Ida M, Dalhoff Kim P, Andersen Jon T, Horwitz Henrik
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Ann Emerg Med. 2025 Jun;85(6):505-511. doi: 10.1016/j.annemergmed.2025.02.001. Epub 2025 Mar 5.
This study investigated the 1-year risk of injuries and poisonings among anabolic androgenic steroid users compared with controls from the general population.
In a cohort study conducted in Denmark, 1,189 anabolic androgenic steroid users were identified through a national antidoping program and matched with 59,450 controls. Participants were followed for 1 year. Data on hospital contacts, educational length, and occupational status were retrieved from nationwide registries. The primary outcomes were the incidence of injuries and poisonings. The secondary outcomes differentiated between fracture and nonfracture injuries, and medicinal versus nonmedicinal causes of poisonings, and described specific causes of injury-related hospital contacts.
Anabolic androgenic steroid users had significantly higher incidences of injuries and poisonings compared with controls. The risk difference for any injury was 7.8% (95% confidence interval [CI] 5.5 to 10.2) and the adjusted hazard ratio (aHR) was 1.46 (95% CI 1.29 to 1.66). Specifically, the risk of fractures was more than doubled among anabolic androgenic steroid users (aHR of 2.23, 95% CI 1.72 to 2.89), with head injuries being particularly prevalent. The risk difference for any poisoning was 1.2% (95% CI 0.5 to 1.9) and the aHR was 2.98 (95% CI 1.82 to 4.90). Medicinal poisoning was the most common poisoning among anabolic androgenic steroid users, with an aHR of 3.53 (95% CI 1.94 to 6.41).
Anabolic androgenic steroid use is associated with an increased risk of both injuries and poisonings, thereby quantifying a substantial risk of external harm among users.
本研究调查了合成代谢雄激素类固醇使用者与普通人群对照组相比，在1年内发生受伤和中毒的风险。
在丹麦进行的一项队列研究中，通过国家反兴奋剂计划确定了1189名合成代谢雄激素类固醇使用者，并与59450名对照组进行匹配。对参与者进行了1年的随访。从全国登记处获取了有关住院情况、受教育年限和职业状况的数据。主要结局是受伤和中毒的发生率。次要结局区分了骨折和非骨折性损伤，以及中毒的药物性与非药物性原因，并描述了与受伤相关的住院情况的具体原因。
与对照组相比，合成代谢雄激素类固醇使用者受伤和中毒的发生率显著更高。任何损伤的风险差异为7.8%（95%置信区间[CI]5.5至10.2），调整后的风险比（aHR）为1.46（95%CI1.29至1.66）。具体而言，合成代谢雄激素类固醇使用者骨折的风险增加了一倍多（aHR为2.23，95%CI1.72至2.89），头部受伤尤为普遍。任何中毒的风险差异为1.2%（95%CI0.5至1.9），aHR为2.98（95%CI1.82至4.90）。药物中毒是合成代谢雄激素类固醇使用者中最常见的中毒类型，aHR为3.53（95%CI1.94至6.41）。
使用合成代谢雄激素类固醇与受伤和中毒风险增加相关，从而量化了使用者面临的重大外部伤害风险。
